Using the model antigen ovalbumin (OVA) to induce a major histocompatibility complex type I (MHCI)-restricted CD8+ T cell response38, we measured tumour-specific responses against subcutaneous EL4 cancer cells expressing OVA (EL4-OVA cells). Here, CD8A is linked to cancer.